Terms: = Pancreatic cancer AND Ki-67
940 results:
1. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract] [Full Text] [Related]
2. Self-assembled nanomicelles for oral delivery of luteolin utilizing the intestinal lymphatic pathway to target pancreatic cancer.
Karole A; Dinakar YH; Sagar P; Mudavath SL
Nanoscale; 2024 Apr; 16(15):7453-7466. PubMed ID: 38517408
[TBL] [Abstract] [Full Text] [Related]
3. Anti-proliferative and apoptotic effect of cannabinoids on human pancreatic ductal adenocarcinoma xenograft in BALB/c nude mice model.
Le TQ; Meesiripan N; Sanggrajang S; Suwanpidokkul N; Prayakprom P; Bodhibukkana C; Khaowroongrueng V; Suriyachan K; Thanasitthichai S; Srisubat A; Surawongsin P; Rungsipipat A; Sakarin S; Rattanapinyopituk K
Sci Rep; 2024 Mar; 14(1):6515. PubMed ID: 38499634
[TBL] [Abstract] [Full Text] [Related]
4. Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.
Olearska H; Sowa-Staszczak A; Morawiec-Sławek K; Kurzyńska A; Kolasa M; Tkacz E; Szumińska M; Hubalewska-Dydejczyk A; Opalinska M
Endokrynol Pol; 2024; 75(1):102-108. PubMed ID: 38497396
[TBL] [Abstract] [Full Text] [Related]
5. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
Yang Z; Chen F; Wei D; Chen F; Jiang H; Qin S
BMC Cancer; 2024 Feb; 24(1):268. PubMed ID: 38408959
[TBL] [Abstract] [Full Text] [Related]
6. Usefulness of intratumoral perfusion analysis for assessing biological features of non-functional pancreatic neuroendocrine neoplasm.
Notake T; Shimizu A; Kubota K; Sugenoya S; Umemura K; Goto T; Yamada A; Fujinaga Y; Soejima Y
Langenbecks Arch Surg; 2024 Jan; 409(1):38. PubMed ID: 38221590
[TBL] [Abstract] [Full Text] [Related]
7. High-grade Solid Pseudopapillary Neoplasms of the Pancreas: Distinct Clinicopathological Malignant Features With Intriguing Gene Alterations through a Comparison With the Conventional Type.
Honda S; Yamaguchi H; Aimono E; Hara S; Minamiguchi S; Norose T; Ohike N; Yamochi T; Yasuda M; Moriya T; Shiko Y; Nishihara H; Nagao T
Am J Surg Pathol; 2024 Mar; 48(3):353-363. PubMed ID: 38189381
[TBL] [Abstract] [Full Text] [Related]
8. Combined utility of ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery.
Li B; Yin X; Ding X; Zhang G; Jiang H; Chen C; Guo S; Jin G
BMC Surg; 2023 Dec; 23(1):370. PubMed ID: 38066512
[TBL] [Abstract] [Full Text] [Related]
9. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
[TBL] [Abstract] [Full Text] [Related]
10. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract] [Full Text] [Related]
11. Preoperative CT histogram analysis to predict the expression of ki-67 in solid pseudopapillary tumours of the pancreas.
Li Z; Xue C; Li S; Jing M; Liu S; Sun J; Ren T; Zhou J
Clin Radiol; 2024 Feb; 79(2):e197-e203. PubMed ID: 38007336
[TBL] [Abstract] [Full Text] [Related]
12. Expression of G protein-coupled receptor GPR19 in normal and neoplastic human tissues.
Gerlach L; Beyer AL; Kaemmerer D; Sänger J; Evert K; Schulz S; Lupp A
Sci Rep; 2023 Nov; 13(1):18993. PubMed ID: 37923782
[TBL] [Abstract] [Full Text] [Related]
13. Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas.
Vesterinen T; Peltola E; Leijon H; Hannula P; Huhtala H; Mäkinen MJ; Nieminen L; Pirinen E; Rönty M; Söderström M; Jaatinen P; Arola J
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894845
[TBL] [Abstract] [Full Text] [Related]
14. Machine Learning-Based Models for Assessing Postoperative Risk Factors in Patients with Cervical cancer.
Yu Z; Zhihui Q; Linrui L; Long L; Qibing W
Acad Radiol; 2024 Apr; 31(4):1410-1418. PubMed ID: 37891091
[TBL] [Abstract] [Full Text] [Related]
15. Radiomics in CT and MR imaging of the liver and pancreas: tools with potential for clinical application.
Berbís MÁ; Godino FP; Rodríguez-Comas J; Nava E; García-Figueiras R; Baleato-González S; Luna A
Abdom Radiol (NY); 2024 Jan; 49(1):322-340. PubMed ID: 37889265
[TBL] [Abstract] [Full Text] [Related]
16. Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.
Morken S; Langer SW; Sundlöv A; Vestermark LW; Ladekarl M; Hjortland GO; Svensson JB; Tabaksblat EM; Haslerud TM; Assmus J; Detlefsen S; Couvelard A; Perren A; Sorbye H
Br J Cancer; 2023 Dec; 129(12):1930-1939. PubMed ID: 37872405
[TBL] [Abstract] [Full Text] [Related]
17. Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.
Kinowaki Y; Fukumura Y; Kawade G; Sugita K; Kinowaki K; Akahoshi K; Kobayashi M; Ono H; Kudo A; Tanabe M; Akashi T; Ohashi K; Kurata M
Gene; 2024 Jan; 893():147916. PubMed ID: 37866661
[TBL] [Abstract] [Full Text] [Related]
18. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
[TBL] [Abstract] [Full Text] [Related]
19. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma.
Koh Y; Kim H; Joo SY; Song S; Choi YH; Kim HR; Moon B; Byun J; Hong J; Shin DY; Park S; Lee KH; Lee KT; Lee JK; Park D; Lee SH; Jang JY; Lee H; Kim JA; Yoon SS; Park JK
J Transl Med; 2023 Oct; 21(1):730. PubMed ID: 37848935
[TBL] [Abstract] [Full Text] [Related]
20. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
PeerJ; 2023; 11():e16237. PubMed ID: 37842043
[TBL] [Abstract] [Full Text] [Related]
[Next]
